These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20515941)

  • 1. Effect of pazopanib on tumor microenvironment and liposome delivery.
    Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
    Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
    Vlahovic G; Rabbani ZN; Herndon JE; Dewhirst MW; Vujaskovic Z
    Br J Cancer; 2006 Oct; 95(8):1013-9. PubMed ID: 17003785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin.
    Fan Y; Du W; He B; Fu F; Yuan L; Wu H; Dai W; Zhang H; Wang X; Wang J; Zhang X; Zhang Q
    Biomaterials; 2013 Mar; 34(9):2277-88. PubMed ID: 23290525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
    Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
    Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
    Gril B; Palmieri D; Qian Y; Anwar T; Ileva L; Bernardo M; Choyke P; Liewehr DJ; Steinberg SM; Steeg PS
    PLoS One; 2011; 6(10):e25625. PubMed ID: 21998674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
    Hamberg P; Verweij J; Sleijfer S
    Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model.
    Jain RK; Tong RT; Munn LL
    Cancer Res; 2007 Mar; 67(6):2729-35. PubMed ID: 17363594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib in ovarian cancer.
    McLachlan J; Banerjee S
    Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
    Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
    Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiogenesis as a hallmark of solid tumors - clinical perspectives.
    Majidpoor J; Mortezaee K
    Cell Oncol (Dordr); 2021 Aug; 44(4):715-737. PubMed ID: 33835425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined anti-angiogenic therapy targeting PDGF and VEGF receptors lowers the interstitial fluid pressure in a murine experimental carcinoma.
    Kłosowska-Wardega A; Hasumi Y; Burmakin M; Ahgren A; Stuhr L; Moen I; Reed RK; Rubin K; Hellberg C; Heldin CH
    PLoS One; 2009 Dec; 4(12):e8149. PubMed ID: 19997591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
    Gremonprez F; Descamps B; Izmer A; Vanhove C; Vanhaecke F; De Wever O; Ceelen W
    Oncotarget; 2015 Oct; 6(30):29889-900. PubMed ID: 26375674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
    Zhu XD; Zhang JB; Fan PL; Xiong YQ; Zhuang PY; Zhang W; Xu HX; Gao DM; Kong LQ; Wang L; Wu WZ; Tang ZY; Ding H; Sun HC
    BMC Cancer; 2011 Jan; 11():28. PubMed ID: 21251271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.
    Ohta M; Kawabata T; Yamamoto M; Tanaka T; Kikuchi H; Hiramatsu Y; Kamiya K; Baba M; Konno H
    Surg Today; 2009; 39(12):1046-53. PubMed ID: 19997799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasound-guided intratumoral administration of collagenase-2 improved liposome drug accumulation in solid tumor xenografts.
    Zheng X; Goins BA; Cameron IL; Santoyo C; Bao A; Frohlich VC; Fullerton GD
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):173-82. PubMed ID: 20306263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical pazopanib blocks VEGF-induced vascular leakage and neovascularization in the mouse retina but is ineffective in the rabbit.
    Iwase T; Oveson BC; Hashida N; Lima e Silva R; Shen J; Krauss AH; Gale DC; Adamson P; Campochiaro PA
    Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):503-11. PubMed ID: 23169884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
    Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.